Ranbaxy is one of India’s largest pharmaceutical companies which exports its products to 125 companies, has ground operations in 43 and manufacturing facilities in eight countries. Currently, Japanese pharma company Daiichi Sankyo has a controlling share (63.92%) in Ranbaxy; a deal which is believed to be worth $4.6 billion.
Ranbaxy to launch anti-malarial drug Synriam in 7 African nations by January 2015
EU lifts drug export ban from Ranbaxy's Toansa plant
Ranbaxy to launch a new anti-malarial drug
Sun Pharma to acquire troubled Ranbaxy for $3.2 billion
Indian pharma to reach new heights but will it be able to maintain quality?
Politics and business interests behind USFDA ban on Ranbaxy: Azad
What led to the USFDA ban on drugs by Ranbaxy?
Ranbaxy banned from distributing drugs in US
Kumble to bat for a healthy heart awareness campaign
Ranbaxy faked data, says Indian whistle blower
US FDA issues import alert against drugs made in Ranbaxy's Mohali unit
Ranbaxy's Indian facilities under scanner: Ghulam Nabi Azad
Ranbaxy ordered to shell out 420,000 dollars as settlement to settle criminal complaints
Ranbaxy goes on mass retrenching spree: Set to fire 400 employees in the next few months
Is this the end of the Ranbaxy fairytale? Japanese owners thinking of renaming company!
Ranbaxy gets assistance from the health ministry
Ranbaxy spurious drugs update: DCGI probe will take a month, Apollo suspends sales
Govt defends India's pharma industry after Ranbaxy fiasco
Ranbaxy spurious drugs case: Indian Medical Association asks DCGI to investigate quality of Ranbaxy drugs in India
Ranbaxy spurious drugs case: Jaslok hospital asks docs not to prescribe Ranbaxy drugs
Ranbaxy spurious drugs case: Indian pharma laws different from that of USFDA
Ranbaxy spurious drugs case: Former Chairman Malvinder Singh hits back at Daiichi Sankyo
Ranbaxy spurious drugs case: Japanese owners Daiichi Sankyo considering legal action against Singh brothers
Will Ranbaxy's mistakes harm Indian pharma's image?
Ranbaxy to launch anti-malarial drug Synriam in 7 African nations by January 2015
EU lifts drug export ban from Ranbaxy's Toansa plant
Ranbaxy to launch a new anti-malarial drug
Sun Pharma to acquire troubled Ranbaxy for $3.2 billion
Indian pharma to reach new heights but will it be able to maintain quality?
Politics and business interests behind USFDA ban on Ranbaxy: Azad
What led to the USFDA ban on drugs by Ranbaxy?
Ranbaxy banned from distributing drugs in US
Kumble to bat for a healthy heart awareness campaign
Ranbaxy faked data, says Indian whistle blower
US FDA issues import alert against drugs made in Ranbaxy's Mohali unit
Ranbaxy's Indian facilities under scanner: Ghulam Nabi Azad
Ranbaxy ordered to shell out 420,000 dollars as settlement to settle criminal complaints
Ranbaxy goes on mass retrenching spree: Set to fire 400 employees in the next few months
Is this the end of the Ranbaxy fairytale? Japanese owners thinking of renaming company!
Ranbaxy gets assistance from the health ministry
Ranbaxy spurious drugs update: DCGI probe will take a month, Apollo suspends sales
Govt defends India's pharma industry after Ranbaxy fiasco
Ranbaxy spurious drugs case: Indian Medical Association asks DCGI to investigate quality of Ranbaxy drugs in India
Ranbaxy spurious drugs case: Jaslok hospital asks docs not to prescribe Ranbaxy drugs
Ranbaxy spurious drugs case: Indian pharma laws different from that of USFDA
Ranbaxy spurious drugs case: Former Chairman Malvinder Singh hits back at Daiichi Sankyo
Ranbaxy spurious drugs case: Japanese owners Daiichi Sankyo considering legal action against Singh brothers
Will Ranbaxy's mistakes harm Indian pharma's image?
